OncoVista Innovative Therapies, Inc. (OVIT)

0.0001 0.0000 (0.00%) At close: 12:28PM EDT

OncoVista Innovative Therapies, Inc.

14785 Omicron Drive
Suite 104
San Antonio, TX 78245
United States
210-677-6000
https://www.oncovista.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Alexander L. Weis Ph.D.	Chairman, CEO, President, CFO, Principal Accounting Officer and Secretary	322k	N/A	1950

Amounts are as of 31 December 2014, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.

Corporate governance

OncoVista Innovative Therapies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.